Key Takeaways
- US business hit by OAI, but warning letter lifted: US revenue fell 21.1% as the Goa Plant 1 OAI classification postponed client milestones and product pickups; the warning letter has since been lifted and an EIR received.
- Domestic business rescued the quarter: India grew 6%+, led by stomatology (17–18%), ophthalmology (11–12%) and the new Cital UTI launch, offsetting a delayed monsoon that marginally hit anti-infective and respiratory.
- Full-year margin and US guidance held despite Q1 softness: Management is confident of 17.5% EBITDA margin and INR280–300 crores US revenue for FY24, with the US ramp-up back-loaded to Q3 and Q4.
- Europe poised for a step-up after a one-off quarter: Both Baddi plants now hold EU GMP approval, batch sizes are being enlarged, and annual Europe guidance stands at INR375–380 crores.
- What to watch next quarter: Whether the promised dramatic turnaround in emerging markets materializes, the pace of the US ramp-up from the INR50-crore quarterly base, and any progress on the OAI remediation timeline for Unit 2.
US Business: OAI Impact and Recovery Path
- OAI hit the quarter directly: US revenue de-grew 21.1% because some customers did not pick up products immediately post-OAI, and milestone payments from clients for products made at the OAI site were postponed by a couple of quarters.
- Warning letter lifted, site cleared: Goa Plant 1 received its EIR from the US FDA and the warning letter was lifted, clearing the way for new solid oral product launches from that site.
- Ramp-up is back-loaded: The climb from the current INR50 crores quarterly run-rate toward INR80 crores will be slow, with more acceleration in Q3 and Q4 than in Q2.
- New launches and partner shifts in motion: A few new solid dosage launches are expected from the other site, and Allopurinol can now be manufactured at that site with the VAI on Plant 1, giving an incremental impact. The company is also actively considering front-ending products through the newly acquired FPP, including some products got back from Teva, with a partner shift timeline of not more than three to four months.
- Combigan launch uncertain: Consequent to the OAI, there will be some back and forth with the front-end partner; management will come back with the impact on this launch.
Aditi Panandikar: "some of the milestones we were to receive from clients for products made at this site. Those have got postponed."
Domestic Formulations: Chronic and Sub-Chronic Drive Growth
- Q1 rescued by chronic and sub-chronic portfolios: Ophthalmology (Excel Division) grew at 11–12% and dental divisions at 17–18%, while new introductions contributed INR6.5 crores, more than double the prior year.
- Stomatology outperformed: Growth came from increased market share, alternate distribution channels, digital media promotion, and a direct-to-consumer channel.
- Urology lifted by Cital franchise: The Cital brand of urinary alkalisers benefited from a long summer, and the new extension Cital UTI for urinary tract infection did exceedingly well.
- Anti-infective and respiratory near pre-COVID levels: These segments reached almost pre-COVID levels with 10% growth on a pre-COVID year, though monsoons delayed by almost a month impacted Q1 marginally. Management noted the industry de-grew 26% and 25% QoQ on these therapies, making Indoco more stable by comparison.
- Full-year India target: Management expects 11–12% minimum growth on the India business for the full year, catching up from the 6% Q1 toward lower double digits.
Aditi Panandikar: "anti-infective and respiratory have been the most challenging two therapies to predict for performance in the last three years or four years... there doesn't seem to be any kind of normalization frankly."
Europe: Poised for a Step-Up
- Q1 was a one-off low quarter: Europe grew only 2.1%, but sustained performance is expected going forward because both Baddi plants have now received EU GMP approval besides the UK, freeing the company to supply all EU countries.
- Batch sizes and profitability improving: Enlarged batch sizes and efficiency gains are expected to improve profitability in the region.
- Annual guidance maintained: Europe revenue guidance stands at INR375–380 crores for FY24.
- Molecule disclosure declined: When asked about specific molecules in Europe beyond Allopurinol and Paracetamol, management declined to disclose names.
Margins: Confident of 17.5% Despite Q1 Headwinds
- Employee expenses stepped up: Employee costs rose roughly INR10 crores QoQ, of which INR3–4 crores was one-time due to an agreement signed at the Goa site, with the rest from regular increments and higher attrition at starting levels.
- Gross margin improvement plan underway: The company is working on a gross margin improvement plan across the organization, geographies and segments.
- Full-year margin commitment: Management feels pretty confident of achieving 17.5% EBITDA margin for the full year FY24.
Aditi Panandikar: "We feel pretty confident that we'll be able to for the full year go up to 17.5%."
Other Businesses and Initiatives
- Emerging markets: Q1 was a one-off quarter; the order book is very strong and a dramatic turnaround is expected from Q2.
- API business: API was very strong in Q1.
- FPP acquisition consolidated: Indoco acquired Florida Pharmaceutical Products, a US distribution and marketing company, consolidated for one month in Q1. The company intends to front-end products through FPP and bring in a couple of solid orders currently done through other partners.
- Digitization push: Apple iPads were given to the field force, an AIML project on machine automation has started, and work is underway on a document management system and HRMS system.
- Domestic strategy: Focus areas include sales force effectiveness, new product launches, exploring new distribution channels, and increasing reach in growth-potential areas.
Regulatory and Remediation
- Unit 2 OAI remediation timeline uncertain: Management is in constant communication with the FDA, hoping for a face-to-face or online call to understand their position and concerns, noting that with four observations they had not expected an OAI. The timeline depends on how the FDA views the strategic proposals sent.
Aditi Panandikar: "We are also, at this time, having constant communication back and forth with FDA, hoping to have a face-to-face or online call at some point to clearly understand their position and concerns because with 4 observations, we had not expected an OAI."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | Achieve 17.5% | Full year FY24 |
| US revenue | INR280–300 crores | Full year FY24 |
| US quarterly run-rate ramp | Grow from INR50 crores to INR80 crores per quarter, with more in Q3 and Q4 | FY24 |
| Europe revenue | INR375–380 crores | Full year FY24 |
| India business growth | Minimum 11–12% growth | Full year FY24 |
| Emerging markets turnaround | Dramatic turnaround from a one-off Q1 | From Q2 FY24 |
| Partner shift to FPP | Shift external partner to internal, not more than 3–4 months | From decision date |
| New US solid oral launches | Few new launches from the other site | Unspecified, FY24 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Consolidated revenue | ₹413.2 cr, +5% YoY |
| Domestic formulations revenue | ₹213 cr, +6.5% YoY |
| International formulations revenue | ₹159.7 cr, -9.9% YoY |
| API business revenue | ₹35.7 cr, +169.2% YoY |
| EBITDA | ₹62.9 cr, 15.2% margin vs 18.1% YoY |
| Profit after tax | ₹25.7 cr, 6.2% margin vs 9.5% YoY |
| Earnings per share | ₹2.81 vs ₹4.17 YoY |
| IPM rank and market share | 31st, 0.58% share (IQVIA Apr-Jun '23) |
| US business revenue | ₹51 cr (per analyst's math), -21.1% YoY |
| Europe business revenue | ₹79.4 cr, +2.1% YoY |
| Emerging markets revenue | ₹25.3 cr, -14.7% YoY |
| FY24 US revenue guidance | ₹280–300 cr |
| FY24 Europe revenue guidance | ₹375–380 cr |
| FY24 EBITDA margin guidance | 17.5% (revised from 18%) |
| Remediation cost (OAI-related) | ₹4 cr incurred in Q1, ~₹4 cr per quarter expected |
| New product introduction contribution | ₹6.5 cr, more than double YoY |